findmyKOL
Clinical trialNCT05398484RecruitingPhase 2/PHASE3Interventional

Psilocybin Therapy in Advanced Cancer

SponsorNYU Langone HealthEnrollment200Advanced Cancer
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of Colorado Anschutz Medical Campus (cu Amc)

    Aurora, Colorado, United States

    Stacy Fischer, MD
    Recruiting
  • Nyu Langone Health

    New York, New York, United States

    Stephen Ross, MD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
24 May 2023
Primary completion
1 Jan 2027
Completion
1 Jan 2027
Last update posted
4 Dec 2025
Registered enrollment
200
Registry id
NCT05398484

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.